WO2010110378A1 - ピラゾール化合物 - Google Patents
ピラゾール化合物 Download PDFInfo
- Publication number
- WO2010110378A1 WO2010110378A1 PCT/JP2010/055257 JP2010055257W WO2010110378A1 WO 2010110378 A1 WO2010110378 A1 WO 2010110378A1 JP 2010055257 W JP2010055257 W JP 2010055257W WO 2010110378 A1 WO2010110378 A1 WO 2010110378A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- salt
- group
- acid
- fluoropyridin
- Prior art date
Links
- 0 C*c1c(*)cc(*)cc1 Chemical compound C*c1c(*)cc(*)cc1 0.000 description 2
- RHZSFRRIEGUIMB-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(cc1S(c2cc(Br)ccc2)(=O)=O)n[n]1-c(cccn1)c1F)=O Chemical compound CC(C)(C)OC(N(C)Cc(cc1S(c2cc(Br)ccc2)(=O)=O)n[n]1-c(cccn1)c1F)=O RHZSFRRIEGUIMB-UHFFFAOYSA-N 0.000 description 1
- JZPGAKBXHZNYOE-UHFFFAOYSA-N CCOC(c(cc1Sc2cc(Br)ccc2)n[n]1-c(cccn1)c1F)=O Chemical compound CCOC(c(cc1Sc2cc(Br)ccc2)n[n]1-c(cccn1)c1F)=O JZPGAKBXHZNYOE-UHFFFAOYSA-N 0.000 description 1
- QHJWZXQQPRIJGT-UHFFFAOYSA-N CNCc(cc1S(c2cccc(C#N)c2)(=O)=O)n[n]1-c(cccn1)c1F Chemical compound CNCc(cc1S(c2cccc(C#N)c2)(=O)=O)n[n]1-c(cccn1)c1F QHJWZXQQPRIJGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present invention relates to a pyrazole compound having acid secretion inhibitory activity.
- proton pump inhibitors represented by omeprazole that suppress gastric acid secretion are widely used in clinical settings.
- existing proton pump inhibitors have problems in terms of effects and side effects.
- existing proton pump inhibitors are often formulated as enteric preparations because they are unstable under acidic conditions. In that case, several hours are required for the onset of action, and the maximum efficacy is achieved by continuous injection. It takes about 5 days to show.
- the existing proton pump inhibitors are expected to be improved because there is concern about the variation in therapeutic effect based on metabolic enzyme polymorphism and drug-drug interactions with drugs such as diazepam.
- Patent Document 1 discloses a formula
- ring A may have 1 to 4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom in addition to a carbon atom as a ring constituent atom, and may be a saturated or unsaturated 5- or 6-membered member.
- An object of the present invention is to provide a compound having a more excellent acid secretion inhibitory action (particularly a proton pump inhibitory action).
- R 1 represents a substituent
- R 2 represents a hydrogen atom, a C 1-6 alkyl group or a cyano group optionally having a halogen atom
- R 3 represents a hydrogen atom, a halogen atom, cyano.
- a C 1-6 alkyl group which may have a halogen atom or a C 1-6 alkoxy group which may have a halogen atom
- one of R 2 and R 3 represents a hydrogen atom
- the other represents a substituent other than a hydrogen atom.
- a salt thereof [hereinafter sometimes abbreviated as compound (I)] unexpectedly has a very strong proton pump inhibitory action and is sufficiently satisfactory as a medicine. And the present invention was completed based on these findings.
- R 1 represents a substituent
- R 2 represents a hydrogen atom, a C 1-6 alkyl group or a cyano group optionally having a halogen atom
- R 3 represents a hydrogen atom, a halogen atom, cyano.
- R 1 represents a substituent
- R 2 represents a hydrogen atom, a C 1-6 alkyl group or a cyano group optionally having a halogen atom
- R 3 represents a hydrogen atom, a halogen atom, cyano.
- a C 1-6 alkyl group which may have a halogen atom or a C 1-6 alkoxy group which may have a halogen atom
- one of R 2 and R 3 represents a hydrogen atom
- the other represents a substituent other than a hydrogen atom.
- the compound (I) of the present invention exhibits an excellent proton pump inhibitory action.
- conventional proton pump inhibitors such as omeprazole and lansoprazole are converted to active form in the acidic environment of gastric wall cells and covalently bound to cysteine residues of H + / K + -ATPase, irreversibly enzymatic activity
- Compound (I) inhibits proton pump (H + / K + -ATPase) activity in a reversible and K + antagonistic inhibition mode, and consequently suppresses acid secretion, It may be called a potassium ion competitive acid blocker (Potassium-Competitive Acid Blocker: P-CAB) or an acid pump antagonist (APA).
- P-CAB potassium ion competitive acid blocker
- APA acid pump antagonist
- Compound (I) has a rapid onset of action, exhibits maximum efficacy from the first administration, and is less affected by genetic polymorphism (variation among patients). Furthermore, by having the substituents R 2 and R 3 at the m-position and p-position of the phenyl group, respectively, the pharmacokinetics are further improved and stronger pharmacology than that of the conventional compound having a proton pump inhibitory action. It is possible to simultaneously impart an action and a lower cytotoxic effect.
- the present invention includes peptic ulcer (eg, gastric ulcer, duodenal ulcer, anastomosis ulcer, ulcer caused by nonsteroidal anti-inflammatory agent, ulcer caused by postoperative stress, etc.), Zollinger-Ellison syndrome, Gastritis, erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease (Symptomatic GERD), Barrett esophagus, functional dyspepsia, gastric cancer, gastric MALT lymphoma, or hyperacidity
- peptic ulcer eg, gastric ulcer, duodenal ulcer, anastomosis ulcer, ulcer caused by nonsteroidal anti-inflammatory agent, ulcer caused by postoperative stress, etc.
- Zollinger-Ellison syndrome eg., Gastritis, erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease (Symptomatic GERD), Barrett esophagus, functional dyspeps
- Compound (I) is useful as a pharmaceutical because it has low toxicity and is excellent in water solubility, pharmacokinetics, and drug efficacy. Since compound (I) is stable even under acidic conditions, it can be orally administered as a normal tablet or the like without making an enteric preparation. For this reason, since preparations, such as a tablet, can be made small, it has the advantage that it becomes easy to take to the sick person with weak swallowing force, especially an elderly person and a dwarf. In addition, since there is no sustained release effect as in the case of enteric preparations, the gastric acid secretion inhibitory action is rapidly manifested, and symptoms such as pain are rapidly improved.
- halogen atom or “halogen” include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- R 1 represents a substituent.
- the “substituent” is preferably a substituent formed of 1 to 7 atoms other than a hydrogen atom, and is a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group or a substituted group. More preferred is a C 1-6 alkoxy group.
- R 1 in the "optionally substituted C 1-6 alkyl group" as the "C 1-6 alkyl group” include methyl, ethyl, n- propyl, isopropyl, n- butyl, isobutyl, sec- butyl Tert-butyl, n-pentyl, sec-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl and the like.
- the substituent of the “C 1-6 alkyl group” includes (1) a halogen atom, (2) nitro, (3) cyano, (4) hydroxy, (5) 1 to 3 halogen atoms.
- C 1-6 alkoxy group eg, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy, fluoromethoxy, etc.
- C 1-6 alkoxy group represented by the “optionally substituted C 1-6 alkoxy group” in R 1 include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec- butoxy, pentyloxy And hexyloxy.
- Examples of the substituent of the “C 1-6 alkoxy group” include the same groups as those described above as the substituent of the “optionally substituted C 1-6 alkyl group”. Is 1 to 5, preferably 1 to 3.
- R 2 represents a hydrogen atom, a C 1-6 alkyl group which may have a halogen atom or a cyano group.
- the “C 1-6 alkyl group” of the “C 1-6 alkyl group optionally having a halogen atom” represented by R 2 is the “optionally substituted C 1-6 exemplified in R 1 ”. Examples thereof include the same as the “C 1-6 alkyl group” of the “alkyl group” and may have 1 to 5, preferably 1 to 3 halogen atoms.
- R 3 represents a hydrogen atom, a halogen atom, a cyano group, a C 1-6 alkyl group which may have a halogen atom or a C 1-6 alkoxy group which may have a halogen atom.
- R "C 1-6 alkyl group which may have a halogen atom” represented by 3 those similar to the "C 1-6 alkyl group which may have a halogen atom” represented by R 2 Is mentioned.
- the “C 1-6 alkoxy group” of the “C 1-6 alkoxy group optionally having a halogen atom” represented by R 3 is the “optionally substituted C 1-6 exemplified in R 1 ”. Examples thereof include the same as the “C 1-6 alkoxy group” of the “alkoxy group”, and may have 1 to 5, preferably 1 to 3 halogen atoms.
- R 2 and R 3 represents a hydrogen atom, while the other represents a substituent other than a hydrogen atom.
- R 1 is more preferably a halogen atom, a cyano group, a methyl group, an ethyl group, a methoxy group, or an ethoxy group, still more preferably a halogen atom, and particularly preferably a fluorine atom.
- R 2 is preferably a hydrogen atom, a C 1-6 alkyl group, or a cyano group, and more preferably a hydrogen atom, a methyl group, or a cyano group.
- R 3 is preferably a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, more preferably a hydrogen atom, a halogen atom, a methyl group or a methoxy group.
- R 3 includes a hydrogen atom, a halogen atom, or a C 1-6 alkoxy group.
- R 3 is preferably a hydrogen atom, a halogen atom or a C 1-3 alkoxy group, more preferably a hydrogen atom, a halogen atom or a methoxy group.
- R 1 is a substituent formed of 1 to 7 atoms other than a hydrogen atom
- R 2 is a hydrogen atom, a C 1-6 alkyl group or a cyano group
- R 3 is a hydrogen atom
- halogen Preferably represents an atom, a C 1-6 alkyl group or a C 1-6 alkoxy group
- one of R 2 and R 3 represents a hydrogen atom
- the other represents a substituent other than a hydrogen atom.
- R 1 is a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group or an optionally substituted C 1-6 alkoxy group
- R 2 is a hydrogen atom, a C 1-6 alkyl group Or a cyano group
- R 3 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group
- one of R 2 and R 3 represents a hydrogen atom
- the other is other than a hydrogen atom It is more preferable to show a substituent.
- the following compounds are particularly preferred.
- Examples of the salt of compound (I) include metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like.
- the metal salt include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt, magnesium salt and barium salt; aluminum salt and the like.
- the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N, N′-dibenzylethylenediamine.
- salts with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, and benzenesulfone. And salts with acid, p-toluenesulfonic acid and the like.
- salts with basic amino acids include salts with arginine, lysine, ornithine and the like
- salts with acidic amino acids include salts with aspartic acid and glutamic acid, for example. It is done.
- an inorganic salt such as an alkali metal salt (eg, sodium salt, potassium salt), an alkaline earth metal salt (eg, calcium salt, magnesium salt, barium salt)
- an inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, phthalic acid, fumaric acid, And salts with organic acids such as oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid and p-toluenesulfonic acid.
- the compounds (Ia) to (XII) in the reaction formula may form a salt.
- Examples of such a salt include the same salts as the salt of the compound (I).
- p represents an integer of 0, 1, 2 and when p is 0 or 1, an appropriate oxidizing agent (eg, hydrogen peroxide, 3-chloroperbenzoic acid, etc.) is used in each compound. By oxidation, p can be converted to a compound of 2.
- Compound (I) is a compound in which p is 2 in compound (Ia).
- the compound obtained in each step can be used in the subsequent reaction as it is in the reaction solution or as a crude product, but can also be isolated from the reaction mixture according to a conventional method, and can be recrystallized, distilled, It can be easily purified by separation means such as chromatography.
- Compound (II) (wherein X is a hydrogen atom; halogen atoms (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), leaving groups such as methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy, etc. Hydroxy group; amino group or mercapto group, R 4 represents a hydrogen atom, formyl group, carboxyl group, ester group, cyano group, methylaminocarbonyl group, etc.) is a commercially available product or is known per se It can be produced according to a method, for example, the method described in Heterocycles, Vol. 46, page 489 (1997), or a method analogous thereto.
- X is a hydrogen atom; halogen atoms (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), leaving groups such as
- Compound (V) (wherein the symbols in the formula are as defined above) is the compound (II) wherein X is a hydrogen atom, halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), methane In the case of a leaving group such as sulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy, etc., compound (II) and compound (III)
- R 2 , R 3 and p are as defined above, and L 1 is a leaving group such as a hydrogen atom, a halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom) or sodium, potassium
- X of the compound (II) is a mercapto group
- the compound (II) and the compound (IV) are a leaving group such as a hydrogen atom, a halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom) or sodium, potassium
- L 2 is a hydrogen atom or halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), methanesulfonyl, p-toluenesulfonyl, etc. It can be produced by reacting with a group.
- halogen atom eg, fluorine atom, chlorine atom, bromine atom, iodine atom
- the amount of compound (III) to be used is about 1 to about 10 mol, preferably about 1 to about 3 mol, per 1 mol of compound (II).
- the amount of compound (IV) to be used is about 1 to about 10 mol, preferably about 1 to about 3 mol, per 1 mol of compound (II).
- This reaction is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds, but hydrocarbons such as benzene and toluene and ethers such as tetrahydrofuran, amides such as N, N-dimethylformamide, N, N-dimethylacetamide or the like Those mixed solvents are preferred.
- the use of a base is effective.
- the base include inorganic bases such as sodium hydride, sodium hydroxide, and potassium hydroxide; basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; potassium ethoxide, potassium tert-butoxide, Metal bases such as sodium methoxide and sodium ethoxide; aromatic amines such as pyridine and lutidine; triethylamine, N-diisopropylethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N, N And tertiary amines such as -dimethylaniline, N-methylpiperidine, N-methylpyrrolidine and N-methylmorpholine.
- the amount of these bases to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (II).
- This reaction can also be carried out in the presence of crown ethers or halogenating agents.
- crown ethers include 15-crown-5-ether and 18-crown-6-ether
- halogenating agents include N-iodosuccinimide, N-bromosuccinimide, N-chlorosuccinimide, bromine Etc.
- the amount of the crown ether and halogenating agent to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (II).
- This reaction can also be performed in the presence of a metal catalyst such as a palladium catalyst.
- a metal catalyst such as a palladium catalyst.
- the palladium catalyst include tetrakis (triphenylphosphine) palladium (0), tris (dibenzylideneacetone) dipalladium, and palladium acetate.
- phosphines include 9,9-dimethyl-4,5-bis (diphenylphosphino) xanthine (XANTOPHOS), 2,2'-bis (diphenylphosphino) -1,1'-binaphthyl (BINAP), and the like. It is done.
- the amount of these palladium catalyst and phosphine to be used is about 0.01 to about 0.5 mol, preferably about 0.01 to about 0.3 mol, per 1 mol of compound (II).
- the reaction time varies depending on the reagent and solvent to be used, but is usually about 30 minutes to about 24 hours, preferably about 30 minutes to about 18 hours.
- the reaction temperature is usually about 0 ° C. to about 150 ° C., preferably about 10 ° C. to about 120 ° C.
- the amount of compound (VI) to be used is about 1 to about 10 mol, preferably about 1 to about 3 mol, per 1 mol of compound (II).
- Compound (VIII) can be produced using compound (V) according to a method similar to the method for producing compound (VII) from compound (II) or a method analogous thereto.
- the compound (VII) can be used in the same manner as the method for producing the compound (V) from the compound (II) or a method analogous thereto.
- Compound (Ia) is compound (IX) when R 4 of compound (VIII) is a formyl group.
- the amount of compound (IX) to be used is about 1 to about 20 mol, preferably about 1 to about 10 mol, per 1 mol of compound (VIII).
- R 4 of compound (VIII) is a hydrogen atom
- the compound (Ia) is, for example, a method described in the 4th edition, Experimental Chemistry Course Vol. 21, pp. 106-124 (1991) (Maruzen Publishing) or the like, or It can be produced by performing formylation by a method according to these and then performing the reductive amination.
- Compound (Ia) is prepared by using a reducing agent such as lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride, or bis (borohydride) calcium when R 4 of compound (VIII) is an ester group. After reducing the ester group, the resulting hydroxy group is converted to chromic acid / pyridine complex, pyridinium chlorochromate, manganese dioxide, sulfur trioxide / pyridine complex or tetra-n-propylammonium perruthenate, etc. After conversion into a formyl group by reacting with an oxidizing agent, it can be produced by carrying out the above reductive amination.
- a reducing agent such as lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride, or bis (borohydride) calcium when R 4 of compound (VIII) is an ester group. After reducing the ester group, the resulting hydroxy group is converted to chromic acid /
- diisobutylaluminum hydride is particularly preferable.
- the amount of these reducing agents to be used is about 0.75 to about 10 equivalents, preferably about 1 to about 5 equivalents, per 1 mol of compound (VIII).
- the oxidizing agent manganese dioxide, sulfur trioxide / pyridine complex or tetra-n-propylammonium perruthenate is preferable.
- the amount of the oxidizing agent to be used is about 0.01 to about 30 equivalents, preferably about 0.05 to about 10 equivalents, per 1 mol of compound (VIII). This oxidation reaction can be performed, for example, according to the method described in Synthesis, page 639 (1994).
- This reaction is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds, but preferred are hydrocarbons such as benzene and toluene, ethers such as tetrahydrofuran and diethyl ether, or a mixed solvent thereof.
- the reaction time varies depending on the reagent and solvent to be used, but is usually about 30 minutes to about 24 hours, preferably about 30 minutes to about 8 hours.
- the reaction temperature is usually about -78 ° C to about 100 ° C, preferably about -78 ° C to about 25 ° C.
- compound (Ia) is reduced using a reducing agent such as diisobutylaluminum hydride and converted to a formyl group, and then the above reductive amination is performed. It can be manufactured by doing.
- diisobutylaluminum hydride is particularly preferable.
- the amount of these reducing agents to be used is about 0.75 to about 10 equivalents, preferably about 1 to about 5 equivalents, per 1 mol of compound (VIII).
- This reaction is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds, but preferred are hydrocarbons such as benzene and toluene, ethers such as tetrahydrofuran and diethyl ether, or a mixed solvent thereof.
- the reaction time varies depending on the reagent and solvent to be used, but is usually about 30 minutes to about 24 hours, preferably about 30 minutes to about 8 hours.
- the reaction temperature is usually about -78 ° C to about 100 ° C, preferably about -78 ° C to about 25 ° C.
- Compound (Ia) can be produced by reduction using a reducing agent when R 4 of compound (VIII) is a methylaminocarbonyl group.
- metal hydrides such as sodium borohydride and lithium aluminum hydride, and boranes such as borane tetrahydrofuran complex are used.
- the amount of the reducing agent to be used is about 0.5 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (VIII).
- an acid catalyst may be added together with the reducing agent.
- Lewis acids such as trifluoroborane diethyl ether complex and aluminum chloride are used.
- the amount of these acid catalysts to be used is about 0.5 to about 10 mol, preferably about 1.0 to about 5.0 mol, relative to compound (VIII).
- This reaction is advantageously performed without a solvent or using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds.
- alcohols such as methanol, ethanol, and propanol
- hydrocarbons such as cyclohexane, hexane, benzene, toluene, xylene, and mesitylene, formic acid, acetic acid, and the like.
- the reaction time is usually about 10 minutes to about 24 hours, preferably about 30 minutes to 12 hours.
- the reaction temperature is usually about 0 to about 120 ° C, preferably about 25 to about 100 ° C.
- compound (Ia) when R 4 of compound (VIII) is an ester group or a carboxyl group, compound (Ia) can be produced by condensation with compound (IX) and subsequent reduction.
- the reaction may be performed in the presence of a suitable condensing agent.
- the condensing agent examples include N, N′-dicarboximides such as N, N′-dicyclohexylcarbodiimide and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (WSC) hydrochloride; N, N′-carbonyl Azolites such as diimidazole; N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, phosphorus oxychloride, dehydrating agents such as acetic anhydride; 2-chloromethylpyridinium iodide, 2-fluoro-1-chloromethyl A 2-halogenopyridinium salt such as pyridinium iodide is used.
- the amount of the condensing agent to be used is about 1 to about 5 mol, preferably about 2 to 3 mol, per 1 mol of compound (VIII).
- the reaction may be carried out in the presence of a base together with a condensing agent.
- a base include basic salts such as potassium acetate and sodium acetate, 1-hydroxy-1H-benzotriazole (HOBt) monohydrate, and the like.
- the amount of the base to be used is about 1 to about 5 mol, preferably about 2 to about 3 mol, per 1 mol of compound (VIII).
- This reaction is advantageously performed using a solvent inert to the reaction.
- solvents include alcohols such as methanol, ethanol, and propanol, hydrocarbons such as cyclohexane, hexane, benzene, toluene, and xylene, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diethyl ether, diisopropyl ether, and the like.
- Ethers N, N-dimethylformamide, N, N-dimethylacetamide, amides such as hexamethylphosphoric triamide, sulfoxides such as dimethyl sulfoxide, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.
- sulfoxides such as dimethyl sulfoxide, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.
- halogenated hydrocarbons acid anhydrides such as acetic anhydride, and mixed solvents thereof.
- the reaction time is usually about 30 minutes to about 48 hours, preferably about 30 minutes to about 24 hours.
- the reaction temperature is usually about 0 to about 120 ° C, preferably about 25 to about 100 ° C.
- Compound (X) (wherein X is as defined above) is a commercially available product, or a method known per se, for example, Journal of American Chemical Society (J. Am. Chem. Soc.), 72 Volume, page 745 (1950), or the like, or a method analogous thereto.
- Compound (XI) can be produced using compound (X) according to the same method as the method for producing compound (V) from compound (II) or a method analogous thereto.
- Compound (XII) can be produced using compound (X) according to a method similar to the method for producing compound (VII) from compound (II) or a method analogous thereto.
- compound (X) is compound (II)
- compound (XI) is compound (V)
- compound (XII) is compound (VII)
- compound (VIII) to compound (Ia ) Can be produced according to the same method as that for producing) or a method analogous thereto.
- Compound (Ia) is prepared by using compound (XI) in the same manner as the method for producing compound (VII) from compound (II), or a method analogous thereto, or compound (XII). It can be produced according to the same method as that for producing compound (V) from II) or a method analogous thereto.
- any of the compounds (Ia) to (XII) in the formula when obtained as a free compound, it can be converted into a target salt by a method known per se or a method analogous thereto, On the other hand, when it is obtained as a salt, it can be converted into a free form or other desired salt by a method known per se or a method analogous thereto.
- Compound (I) can be isolated and purified by known means such as phase transfer, concentration, solvent extraction, fractional distillation, liquid conversion, crystallization, recrystallization, chromatography and the like.
- compound (I) When compound (I) is obtained as a free compound, it can be converted to the target salt by a method known per se or a method analogous thereto, and conversely, when it is obtained as a salt, it is known per se. It can be converted into a free form or other desired salt by the method or a method analogous thereto.
- Compound (I) may be used as a prodrug.
- a prodrug of compound (I) is a compound that is converted to compound (I) by a reaction with an enzyme, gastric acid, or the like under physiological conditions in vivo, that is, compound (I) that is enzymatically oxidized, reduced, hydrolyzed, etc.
- a compound in which the amino group of the compound (I) is acylated, alkylated or phosphorylated for example, the amino group of the compound (I) is eicosanoylated, alanylated, pentylaminocarbonylated) , (5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation, t-butylated compounds, etc.
- Compounds in which the hydroxy group of compound (I) is acylated, alkylated, phosphorylated, borated for example, the hydroxy group of compound (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated , Alanylated, dimethylaminomethylcarbonyl
- prodrug of compound (I) changes to compound (I) under physiological conditions as described in Hirokawa Shoten 1990, “Drug Development”, Volume 7, pages 163 to 198. There may be.
- any one of the isomers and a mixture are included in the compound (I).
- the optical isomer resolved from the racemate is also encompassed in compound (I).
- Each of these isomers can be obtained as a single product by a known synthesis method or separation method (concentration, solvent extraction, column chromatography, recrystallization, etc.).
- the compound (I) may be a crystal, and it is included in the compound (I) regardless of whether the crystal form is single or a crystal form mixture.
- the crystal can be produced by crystallization by applying a crystallization method known per se.
- Compound (I) may be a solvate (for example, a hydrate) or a non-solvate, and both are encompassed in compound (I).
- the compound (I) of the present invention or a prodrug thereof (hereinafter sometimes abbreviated as the compound of the present invention) has a proton pump inhibitory action and effectively suppresses secretion of gastric acid. In addition, it has low toxicity (eg acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity, etc.), high water solubility, stability, pharmacokinetics (absorbability, distribution) , Metabolism, excretion, etc.)
- the compound of the present invention is used in mammals (eg, humans, monkeys, sheep, cows, horses, dogs, cats, rabbits, rats, mice, etc.) peptic ulcers (eg, gastric ulcer, duodenal ulcer, anastomotic ulcer, non-steroid Ulcers caused by systemic anti-inflammatory agents, ulcers caused by postoperative stress, etc.); Zollinger-Ellison syndrome; gastritis; erosive esophagitis; reflux esophagitis such as erosive reflux esophagitis; non-erosive Symptomatic gastroesophageal reflux disease such as gastroesophageal reflux disease or gastroesophageal reflux disease without esophagitis (Symptomatic ⁇ Gastroesophageal Reflux Disease (Symptomatic GERD)); Barrett's esophagus; Functional dyspepsia; gastric cancer (interleukin-1) Gastric cancer associated with the promotion of interleukin-1 ⁇ production by genetic polymorph
- reflux esophagitis erosive esophagitis
- symptomatic gastroesophageal reflux disease Symptomatic Gastroesophageal Reflux Disease (Symptomatic GERD)
- GERD Symptomatic Gastroesophageal Reflux Disease
- the content of the compound of the present invention in the pharmaceutical composition of the present invention is about 0.01 to 100% by weight of the whole composition.
- the dose varies depending on the administration subject, administration route, disease and the like, but for example, when administered orally to an adult (60 kg) as an anti-ulcer agent, the active ingredient is about 0.5 to about 1500 mg / day, preferably Is about 5 to about 150 mg / day.
- the compound of the present invention may be administered once a day or divided into 2 to 3 times a day.
- the compound of the present invention is low in toxicity and is used as it is or in accordance with a method known per se, a pharmaceutical composition mixed with a pharmacologically acceptable carrier, such as tablets (including sugar-coated tablets and film-coated tablets), powders, granules, Oral or parenteral (eg, topical, rectal) preparations such as capsules (including soft capsules), orally disintegrating tablets, orally disintegrating films, solutions, injections, suppositories, sustained-release agents, and patches. , Intravenous administration, etc.). In particular, it is suitably administered as an oral preparation as a tablet, granule, capsule or the like.
- a pharmacologically acceptable carrier such as tablets (including sugar-coated tablets and film-coated tablets), powders, granules, Oral or parenteral (eg, topical, rectal) preparations such as capsules (including soft capsules), orally disintegrating tablets, orally disintegrating films, solutions, injections, sup
- Examples of pharmacologically acceptable carriers that may be used in the production of the pharmaceutical composition of the present invention include various organic or inorganic carrier substances that are commonly used as pharmaceutical materials.
- the additives include binders, disintegrants, water-soluble polymers, basic inorganic salts; solvents, solubilizers, suspending agents, isotonic agents, buffering agents, soothing agents and the like in liquid preparations. Further, if necessary, additives such as ordinary preservatives, antioxidants, colorants, sweeteners, sour agents, foaming agents, and fragrances can be used.
- Examples of the “excipient” include lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid, titanium oxide and the like.
- Examples of the “lubricant” include magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid and the like.
- Examples of the “binder” include hydroxypropylcellulose, hydroxypropylmethylcellulose, crystalline cellulose, starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan, low-substituted hydroxypropylcellulose, and the like.
- disintegrant examples include (1) crospovidone, (2) croscarmellose sodium (FMC-Asahi Kasei Co., Ltd.), carmellose calcium (manufactured by Gotoku Pharmaceutical), and other disintegrants called super disintegrants, (3) Sodium carboxymethyl starch (eg, Matsutani Chemical Co., Ltd.), (4) Low-substituted hydroxypropyl cellulose (eg, Shin-Etsu Chemical Co., Ltd.), (5) Corn starch, etc.
- the “crospovidone” is crosslinked with a chemical name of 1-ethenyl-2-pyrrolidinone homopolymer, including those called polyvinylpolypyrrolidone (PVPP) and 1-vinyl-2-pyrrolidinone homopolymer.
- PVPP polyvinylpolypyrrolidone
- Examples of the polymer may include any of the following polymers, and specific examples include Kollidon CL (manufactured by BASF), Polyplaston XL (manufactured by ISP), Polyplaston XL-10 (manufactured by ISP), and Polyplastidone.
- INF-10 manufactured by ISP.
- water-soluble polymer examples include ethanol-soluble water-soluble polymers [eg, cellulose derivatives such as hydroxypropylcellulose (hereinafter sometimes referred to as HPC), polyvinylpyrrolidone, etc.], ethanol-insoluble water-soluble polymers Molecule [for example, hydroxypropylmethylcellulose (hereinafter sometimes referred to as HPMC), cellulose derivatives such as methylcellulose, sodium carboxymethylcellulose, sodium polyacrylate, polyvinyl alcohol, sodium alginate, guar gum, etc.] and the like.
- HPMC hydroxypropylmethylcellulose
- basic inorganic salt examples include basic inorganic salts of sodium, potassium, magnesium and / or calcium. Preferred is a basic inorganic salt of magnesium and / or calcium.
- a basic inorganic salt of magnesium More preferred is a basic inorganic salt of magnesium.
- the basic inorganic salt of sodium include sodium carbonate, sodium hydrogen carbonate, disodium hydrogen phosphate and the like.
- Examples of the basic inorganic salt of potassium include potassium carbonate and potassium hydrogen carbonate.
- Examples of the basic inorganic salt of magnesium include heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicate, magnesium aluminate, synthetic hydrotalcite [Mg 6 Al 2 ( OH) 16 ⁇ CO 3 ⁇ 4H 2 O] and alumina hydroxide / magnesium, preferably heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide and the like.
- Examples of the basic inorganic salt of calcium include precipitated calcium carbonate and calcium hydroxide.
- Examples of the “solvent” include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
- Examples of the “solubilizing agent” include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- the “suspending agent” examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; And hydrophilic polymers such as polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose.
- examples of the “isotonic agent” include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
- Examples of the “buffering agent” include buffer solutions of phosphate, acetate, carbonate, citrate, and the like.
- Examples of the “soothing agent” include benzyl alcohol.
- Examples of the “preservative” include p-hydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Examples of the “antioxidant” include sulfite, ascorbic acid, ⁇ -tocopherol and the like.
- Examples of the “coloring agent” include edible pigments such as edible yellow No. 5, edible red No. 2, and edible blue No. 2; edible lake pigments, bengara and the like.
- sweetening agent examples include saccharin sodium, dipotassium glycyrrhizin, aspartame, stevia, thaumatin and the like.
- sweetening agent examples include citric acid (anhydrous citric acid), tartaric acid, malic acid and the like.
- fuming agent examples include sodium bicarbonate.
- fragment may be a synthetic product or a natural product, and examples thereof include lemon, lime, orange, menthol, and strawberry.
- the compound of the present invention is compression-molded according to a method known per se, for example, by adding a carrier such as an excipient, a disintegrant, a binder or a lubricant, and then, if necessary, masking of taste, enteric properties or sustainability. Therefore, it is possible to obtain a preparation for oral administration by coating by a method known per se.
- a carrier such as an excipient, a disintegrant, a binder or a lubricant
- an intermediate layer may be provided between the enteric layer and the drug-containing layer by a method known per se for the purpose of separating both layers.
- a core containing crystalline cellulose and lactose is coated with the compound of the present invention and, if necessary, a basic inorganic salt, and further coated with a coating layer containing a water-soluble polymer.
- the resulting composition is coated with a polyethylene glycol-containing enteric coating layer, then coated with a triethyl citrate-containing enteric coating layer, and further coated with a polyethylene glycol-containing enteric coating layer. It can be produced by a method of coating with mannitol to obtain fine particles, mixing the obtained fine particles and additives, and molding.
- enteric coating layer examples include cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose phthalate, hydroxymethylcellulose acetate succinate, methacrylic acid copolymer [for example, Eudragit L30D-55 (trade name; Rame Co., Ltd.), Kollicoat MAE30DP (trade name; manufactured by BASF), Polykid PA30 (trade name; manufactured by Sanyo Kasei Co., Ltd.), etc.], water-based enteric polymer bases such as carboxymethyl ethyl cellulose and shellac; Sustained release bases such as coalescent [eg Eudragit NE30D (trade name), Eudragit RL30D (trade name), Eudragit RS30D (trade name), etc.]; water-soluble polymer; triethyl citrate, polyethylene glycol, acetylated monoglyceride, A kind of plasticizer such as triacetin and castor oil Others include a layer formed of such a mixture of two or more.
- CAP
- additives examples include water-soluble sugar alcohols (eg, sorbitol, mannitol and maltitol, reduced starch saccharified product, xylitol, reduced palatinose, erythritol, etc.), crystalline cellulose (eg, Theolas KG 801, Avicel PH 101) , Avicel PH 102, Avicel PH 301, Avicel PH 302, Avicel RC-591 (crystalline cellulose / carmellose sodium), etc., low-substituted hydroxypropylcellulose (eg, LH-22, LH-32, LH-23, LH) -33 (Shin-Etsu Chemical Co., Ltd.) and mixtures thereof, etc.), binders, acidulants, foaming agents, sweeteners, fragrances, lubricants, colorants, stabilizers, excipients, Disintegrants are also used.
- water-soluble sugar alcohols eg, sorbitol, mannitol and
- the compound of the present invention may be used in combination with 1 to 3 other active ingredients.
- other active ingredients include anti-Helicobacter pylori active substances, imidazole compounds, bismuth salts, quinolone compounds, and the like.
- anti-Helicobacter pylori active substance examples include penicillin antibiotics (eg, amoxicillin, benzylpenicillin, piperacillin, mecillinam, ampicillin, temocillin, bacampicillin, aspoxillin (bacampicillin), aspoxicillin), sultamicillin, lenampicillin, etc.), cephem antibiotics (eg, cefixime, cefaclor, etc.), macrolide antibiotics (eg, erythromycin, clarithromycin, roxithromycin, rokithromycin) (rokitamycin), flurithromycin, telithromycin, etc.), tetracycline antibiotics (eg, tetracycline, minocycline, streptomycin, etc.), aminoglycoside antibiotics (eg, gelithomycin) Tamaishin, amikacin, etc.), imipenem and the like.
- penicillin antibiotics eg, amoxicillin, benzylpen
- penicillin antibiotics and macrolide antibiotics are preferred.
- examples of the “imidazole compound” include metronidazole, miconazole and the like.
- examples of the “bismuth salt” include bismuth acetate, bismuth citrate, bismuth subsalicylate and the like.
- examples of the “quinolone compound” include ofloxacin, cyproxacin and the like.
- penicillin antibiotics eg, amoxicillin, etc.
- erythromycin antibiotics eg, clarithromycin, etc.
- the compound of the present invention alone has an anti-H. Pylori action (bacteriostatic action or sterilization action), but the antibacterial action of other antibiotics by its gastric pH regulating action, etc. It can be enhanced and also plays an auxiliary role in the sterilization effect based on the action of antibiotics used in combination.
- the “other active ingredient” and the compound (I) of the present invention are mixed according to a method known per se, and a single pharmaceutical composition (eg, tablet, powder, granule, capsule (including soft capsule), liquid, Injections, suppositories, sustained-release preparations, etc.) may be formulated and used together, or each may be formulated separately and administered to the same subject simultaneously or with a time difference.
- a single pharmaceutical composition eg, tablet, powder, granule, capsule (including soft capsule), liquid, Injections, suppositories, sustained-release preparations, etc.
- the compound of the present invention is a gastrointestinal motility promoter, a drug acting on the lower esophageal sphincter (eg, a transient lower esophageal sphincter relaxation inhibitor, etc.), a ClC-2 channel opener (ClC-2 channel opener) (Promoters), histamine H 2 receptor antagonists, antacids, sedatives, gastric digestives or nonsteroidal anti-inflammatory drugs (NSAIDs).
- gastrointestinal motility promoter include domperidone, metoclopramide, mosapride, itopride, tegaserod and the like.
- Examples of the “drug that acts on the lower esophageal sphincter” include GABA-B receptor agonists such as baclofen and optically active forms thereof, glutamine receptor antagonists, and the like.
- Examples of the “ClC-2 channel opener (intestinal secretion promoting agent)” include rubiprostone.
- Examples of the “histamine H 2 receptor antagonist” include cimetidine, ranitidine, famotidine, roxatidine, nizatidine, lafutidine and the like.
- Examples of the “antacid” include sodium hydrogen carbonate, aluminum hydroxide and the like.
- Examples of the “sedative” include diazepam and chlordiazepoxide.
- Examples of the “healthy stomach digestive agent” include gentian, assembly, diastase and the like.
- Examples of the “non-steroidal anti-inflammatory agent” include aspirin, indomethacin, ibuprofen, mefenamic acid, diclofenac, etodolac, piroxicam, celecoxib and the like.
- Gastrointestinal motility stimulants drugs that act on the lower esophageal sphincter, ClC-2 channel openers (intestinal secretion promoters), histamine H 2 receptor antagonists, antacids, sedatives, healthy gastrointestinal drugs, or nonsteroidal
- the anti-inflammatory agent and the compound (I) of the present invention are mixed according to a method known per se, and one pharmaceutical composition (eg, tablet, powder, granule, capsule (including soft capsule), liquid, injection, suppository) Preparations, sustained release preparations, etc.) may be formulated and used together, or each may be formulated separately and administered to the same subject simultaneously or with a time lag.
- the compound of the present invention may also be used in combination with the following drugs.
- proton pump inhibitors eg, omeprazole, esomeprazole, pantoprazole, rabeprazole, tenatoprazole, ilaprazole and lansoprazole
- oral antacid combinations e.g., Maalox, Aludrox and Gaviscon
- mucosal protective agents e.g., polaprezinc, ecabe sodium, rebamipide, teprenone, cetraxate, sucralfate, chloropylline-copper and Plaunotol
- anti-gastric agents e.g., anti-gastrin vaccine, itriglumide and Z-360
- 5-HT 3 antagonists e.g., dolasetron, palonosetron, alosetron, azasetron, ramosetron, miraza
- GABA B agonists e.g., baclofen and AZD-3355
- GABA B antagonists e.g., GAS-360 and SGS-742
- calcium channel blockers e.g., aranidipine, lacidipine, falodipine, azelnidipine, clinidipine, lomerizine, diltiazem, gallopamil, gallopamil (efonidipine), nisolpidine (nisoldipine), amlodipine (amlodipine), lercanidipine (lercanidipine), bevantolol, nicardipine (nicardipine), isradipine (isradipine), benidipine, verapamil, endipinepine (nitripine) (b
- the above drugs (i) to (xvi) and the compound (I) of the present invention are mixed according to a method known per se, and a single pharmaceutical composition (for example, tablets, powders, granules, capsules (including soft capsules)) , Solutions, injections, suppositories, sustained-release agents, etc.) may be formulated and used together, or each may be formulated separately and administered to the same subject simultaneously or with a time difference.
- a single pharmaceutical composition for example, tablets, powders, granules, capsules (including soft capsules)
- Solutions, injections, suppositories, sustained-release agents, etc. may be formulated and used together, or each may be formulated separately and administered to the same subject simultaneously or with a time difference.
- “Room temperature” in the following Reference Examples and Examples usually indicates a range of about 10 ° C. to about 35 ° C., but is not particularly limited.
- the mixing ratio of the liquid indicates a volume ratio.
- “%” Indicates weight percent unless otherwise specified. However, the yield indicates mol / mol%.
- Silica gel column chromatography is MERCK silica gel 60 (0.063-0.200mm), Fuji Silysia Chemical Ltd. Chromatorex (trade name) NH (described as basic silica gel column chromatography) or MORITEX Purif-Pack (silica gel column chromatography). Chromatography or basic silica gel column chromatography).
- reaction solution was stirred at room temperature for 1 hour, treated with 1 mol / L hydrochloric acid, and extracted with ethyl acetate.
- the extract was washed with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound as a yellow solid (yield 135 mg, 89%).
- reaction solution was stirred at 0 ° C. for 2 hours, treated with 1 mol / L hydrochloric acid, and extracted with ethyl acetate.
- the extract was washed with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound as a yellow oil (yield 371 mg, 88%).
- Example 1 1- ⁇ 5-[(4-Fluorophenyl) sulfonyl] -1- (2-fluoropyridin-3-yl) -1H-pyrazol-3-yl ⁇ -N-methylmethanamine hydrochloride ( ⁇ 5-[(4-Fluorophenyl) sulfonyl] -1- (2-fluoropyridin-3-yl) -1H-pyrazol-3-yl ⁇ methyl) methylcarbamate tert-butyl (132 mg) was added to ethyl acetate (2 mL ) And 2-propanol (1 mL), and a 4 mol / L hydrogen chloride-ethyl acetate solution (3 mL) was added.
- Example 2 1- ⁇ 1- (2-Fluoropyridin-3-yl) -5-[(4-methoxyphenyl) sulfonyl] -1H-pyrazol-3-yl ⁇ -N-methylmethanamine hydrochloride After reductive amination of 1- (2-fluoropyridin-3-yl) -5-[(4-methoxyphenyl) sulfonyl] -1H-pyrazole-3-carbaldehyde using the same method as in Reference Example 7 And 4 mol / L hydrogen chloride-ethyl acetate solution. Mp 222-225 ° C.
- Example 3 1- ⁇ 1- (2-Fluoropyridin-3-yl) -5-[(3-methylphenyl) sulfonyl] -1H-pyrazol-3-yl ⁇ -N-methylmethanamine hydrochloride ( ⁇ 1- (2-Fluoropyridin-3-yl) -5-[(3-methylphenyl) sulfonyl] -1H-pyrazol-3-yl ⁇ methyl) methylcarbamate tert-butyl (302 mg) in ethyl acetate (2 mL ) And 2-propanol (1 mL), and a 4 mol / L hydrogen chloride-ethyl acetate solution (3 mL) was added.
- Example 4 3-( ⁇ 1- (2-Fluoropyridin-3-yl) -3-[(methylamino) methyl] -1H-pyrazol-5-yl ⁇ sulfonyl) benzonitrile hydrochloride ( ⁇ 5-[(3-Cyanophenyl) sulfonyl] -1- (2-fluoropyridin-3-yl) -1H-pyrazol-3-yl ⁇ methyl) methylcarbamate tert-butyl (247 mg) in ethyl acetate (2 mL ) And 2-propanol (1 mL), and a 4 mol / L hydrogen chloride-ethyl acetate solution (3 mL) was added.
- Test example 1 Proton Potassium-Adenosine Triphosphatase (H + , K + -ATPase) Inhibitory Activity Test Gastric mucosa microsomal fraction according to the method of Wallmark et al. [Biochim. Biophys. Acta, 728, 31 (1983)] Were prepared from porcine stomach. First, the stomach part was removed, washed with tap water, immersed in 3 mol / L saline, and the mucosal surface was wiped with a paper towel.
- the gastric mucosa was exfoliated and finely cut, and then homogenized using polytron (Kinematica) in 0.25 mol / L sucrose solution (pH 6.8) containing 1 mmol / L EDTA and 10 mmol / L Tris-HCl.
- the resulting homogenate was centrifuged at 20,000 ⁇ g for 30 minutes, and the supernatant was centrifuged at 100,000 ⁇ g for 90 minutes.
- the precipitate was suspended in 0.25 mol / L sucrose solution, overlaid on 0.25 mol / L sucrose solution containing 7.5% Ficoll, and centrifuged at 100,000 ⁇ g for 5 hours. The interface fraction of both layers was collected and washed with 0.25 mol / L sucrose solution by centrifugation.
- the obtained microsomal fraction was used as a proton, potassium-adenosine triphosphatase preparation.
- Test example 2 The pKa value was obtained by calculation using Physchem Batch (Ver. 10) of Advanced Chemistry Developmet, Inc. The results are shown in Table 1.
- Test example 3 ATP content test Human hepatoma-derived cell line HepG2 is 10% fetal bovine serum (FBS; TRACE SCIENTIFIC LTD.), 1 mmol / L sodium pyruvate (Invitrogen), 2 mmol / Maintained and passaged at 37 ° C with 5% CO 2 using Dulbecco's modified Eagle medium (DMEM; Invitrogen) containing L L-glutamine (Invitrogen), 50 IU / mL penicillin (Invitrogen), 50 ⁇ g / mL streptomycin (Invitrogen) did.
- FBS fetal bovine serum
- Invitrogen 1 mmol / L sodium pyruvate
- DMEM Dulbecco's modified Eagle medium
- test reagent was prepared to 10 mM in DMSO, and further DMSO using DMEM medium containing 0.5% FBS, 1 mmol / L sodium pyruvate, 2 mmol / L L-glutamine, 50 IU / mL penicillin, 50 ⁇ g / mL streptomycin. The final concentration of was diluted to 0.1%.
- HepG2 (2 ⁇ 10 4 cells / well) was cultured on a 96-well white plate (Costar) together with the test reagent at 5% CO 2 and 37 ° C. After 1 day of culture, the intracellular ATP content was measured using ATPLite TM (PerkinElmer Life Sciences). The results are shown in Table 1 as relative values (%) with respect to the control (no drug added) at 100 ⁇ M (n ⁇ 3, mean value ⁇ SD).
- Test example 4 Caspase-3 / 7 Activity Test Caspase-3 / 7 activity in cells cultured for 1 day in the same manner as in Test Example 3 was measured using Caspase-Glo 3/7 Assay (Promega). The relative activity of each test reagent (%) with the maximum value of Caspase-3 / 7 activity when exposed to staurosporine as 100% and the activity without addition of the test reagent as 0%. As shown in Table 1 (n ⁇ 3, mean ⁇ SD). Test Example 5 Inhibition test of histamine-stimulated acid secretion in anesthetized rats Seven-week-old Jcl: SD male rats were fasted for about 24 hours and then used for experiments.
- the acid secretion inhibition rate of the test drug was determined from comparison with the control.
- the results are shown in Table 1. From the results in Table 1, it can be seen that the compound (I) of the present invention has an excellent H + / K + -ATPase inhibitory activity and a low pKa value, and has extremely low cytotoxicity even at a high concentration. In addition, a strong acid secretion inhibitory effect is confirmed in rat intravenous administration.
- the compound (I) of the present invention exhibits an excellent proton pump inhibitory action.
- conventional proton pump inhibitors such as omeprazole and lansoprazole are converted to active form in the acidic environment of gastric wall cells and covalently bound to cysteine residues of H + / K + -ATPase, irreversibly enzymatic activity
- compound (I) inhibits proton pump (H + / K + -ATPase) activity in a reversible and K + antagonistic manner, resulting in suppression of acid secretion.
- P-CAB potassium ion competitive acid blocker
- APA acid pump antagonist
- Compound (I) has a rapid onset of action, exhibits maximum efficacy from the first administration, and is less affected by genetic polymorphism (variation among patients). Furthermore, by having the substituents R 2 and R 3 at the m-position and p-position of the phenyl group, respectively, the pharmacokinetics are further improved and stronger pharmacology than that of the conventional compound having a proton pump inhibitory action. It is possible to simultaneously impart an action and a lower cytotoxic effect.
- the present invention includes peptic ulcer (eg, gastric ulcer, duodenal ulcer, anastomosis ulcer, ulcer caused by nonsteroidal anti-inflammatory agent, ulcer caused by postoperative stress, etc.), Zollinger-Ellison syndrome, Gastritis, erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease (Symptomatic GERD), Barrett esophagus, functional dyspepsia, gastric cancer, gastric MALT lymphoma, or hyperacidity
- peptic ulcer eg, gastric ulcer, duodenal ulcer, anastomosis ulcer, ulcer caused by nonsteroidal anti-inflammatory agent, ulcer caused by postoperative stress, etc.
- Zollinger-Ellison syndrome eg., Gastritis, erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease (Symptomatic GERD), Barrett esophagus, functional dyspeps
- Compound (I) is useful as a pharmaceutical because it has low toxicity and is excellent in water solubility, pharmacokinetics, and drug efficacy. Since compound (I) is stable even under acidic conditions, it can be orally administered as a normal tablet or the like without making an enteric preparation. For this reason, since preparations, such as a tablet, can be made small, it has the advantage that it becomes easy to take to the sick person with weak swallowing force, especially an elderly person and a dwarf. In addition, since there is no sustained release effect as in the case of enteric preparations, the gastric acid secretion inhibitory action is rapidly manifested, and symptoms such as pain are rapidly improved. This application is based on patent application No. 2009-077078 filed in Japan, the contents of which are incorporated in full herein.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
で表される化合物が記載されている。
〔1〕式(I)
〔2〕R1が、水素原子以外の原子数1~7個で形成される置換基である上記〔1〕記載の化合物またはその塩、
〔3〕R1が、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基または置換されていてもよいC1-6アルコキシ基である上記〔1〕記載の化合物またはその塩、
〔4〕R2が、水素原子、C1-6アルキル基またはシアノ基である上記〔1〕記載の化合物またはその塩、
〔5〕R3が、水素原子、ハロゲン原子、C1-6アルキル基またはC1-6アルコキシ基である上記〔1〕記載の化合物またはその塩、
〔6〕1-{5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩、
〔7〕1-{1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩、
〔8〕1-{1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩、
〔9〕3-({1-(2-フルオロピリジン-3-イル)-3-[(メチルアミノ)メチル]-1H-ピラゾール-5-イル}スルホニル)ベンゾニトリルまたはその塩、
〔10〕上記〔1〕記載の化合物またはその塩のプロドラッグ、
〔11〕上記〔1〕記載の化合物もしくはその塩またはそのプロドラッグを含有してなる医薬、
〔12〕酸分泌抑制剤である上記〔11〕記載の医薬、
〔13〕カリウムイオン競合型アシッドブロッカー(Potassium-Competitive Acid Blocker)である上記〔11〕記載の医薬、
〔14〕消化性潰瘍、ゾリンジャー・エリソン(Zollinger-Ellison)症候群、胃炎、逆流性食道炎、症候性胃食道逆流症(Symptomatic Gastroesophageal Reflux Disease(Symptomatic GERD))、Barrett食道、機能性ディスペプシア(Functional Dyspepsia)、胃癌、胃MALTリンパ腫、非ステロイド系抗炎症剤に起因する潰瘍あるいは手術後ストレスによる胃酸過多ならびに潰瘍の治療もしくは予防剤;または消化性潰瘍、急性ストレス潰瘍、出血性胃炎あるいは侵襲ストレスによる上部消化管出血の抑制剤である上記〔11〕記載の医薬、
〔15〕哺乳動物に対して、上記〔1〕記載の化合物もしくはそれらの塩またはそのプロドラッグの有効量を投与することを特徴とする消化性潰瘍、ゾリンジャー・エリソン(Zollinger-Ellison)症候群、胃炎、逆流性食道炎、症候性胃食道逆流症(Symptomatic Gastroesophageal Reflux Disease(Symptomatic GERD))、Barrett食道、機能性ディスペプシア(Functional Dyspepsia)、胃癌、胃MALTリンパ腫、非ステロイド系抗炎症剤に起因する潰瘍あるいは手術後ストレスによる胃酸過多ならびに潰瘍の治療または予防方法;または消化性潰瘍、急性ストレス潰瘍、出血性胃炎あるいは侵襲ストレスによる上部消化管出血の抑制方法、および
〔16〕消化性潰瘍、ゾリンジャー・エリソン(Zollinger-Ellison)症候群、胃炎、逆流性食道炎、症候性胃食道逆流症(Symptomatic Gastroesophageal Reflux Disease(Symptomatic GERD))、Barrett食道、機能性ディスペプシア(Functional Dyspepsia)、胃癌、胃MALTリンパ腫、非ステロイド系抗炎症剤に起因する潰瘍あるいは手術後ストレスによる胃酸過多ならびに潰瘍の治療もしくは予防剤;または消化性潰瘍、急性ストレス潰瘍、出血性胃炎あるいは侵襲ストレスによる上部消化管出血の抑制剤を製造するための上記〔1〕記載の化合物もしくはその塩またはそれらのプロドラッグの使用に関する。
式(I)としては、R1が水素原子以外の原子数1~7個で形成される置換基、R2が水素原子、C1-6アルキル基またはシアノ基、R3が水素原子、ハロゲン原子、C1-6アルキル基またはC1-6アルコキシ基を示し、R2およびR3のいずれか一方は水素原子を示し、他方は水素原子以外の置換基を示すのが好ましく、式(I)として、R1がハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基または置換されていてもよいC1-6アルコキシ基、R2が水素原子、C1-6アルキル基またはシアノ基、R3が水素原子、ハロゲン原子、C1-6アルキル基またはC1-6アルコキシ基を示し、R2およびR3のいずれか一方は水素原子を示し、他方は水素原子以外の置換基を示すのが、より好ましい。
1-{5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩。
1-{1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩。
1-{1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩。
3-({1-(2-フルオロピリジン-3-イル)-3-[(メチルアミノ)メチル]-1H-ピラゾール-5-イル}スルホニル)ベンゾニトリルまたはその塩。
化合物(IV)の使用量は、化合物(II)1モルに対し、約1~約10モル、好ましくは約1~約3モルである。
(i)プロトンポンプ阻害薬、例、オメプラゾール(omeprazole)、エソメプラゾール(esomeprazole)、パントプラゾール(pantoprazole)、ラベプラゾール(rabeprazole)、テナトプラゾール(tenatoprazole)、イラプラゾール(ilaprazole)およびランソプラゾール(lansoprazole);
(ii)経口制酸合剤、例、Maalox、AludroxおよびGaviscon;
(iii)粘膜保護剤、例、ポラプレジンク(polaprezinc)、エカベトナトリウム(ecabe sodium)、レバミピド(rebamipide)、テプレノン(teprenone)、セトラキサート(cetraxate)、スクラルファート(sucralfate)、クロロピリン銅(chloropylline-copper)およびプラウノトール(plaunotol);
(iv)抗胃剤、例、抗ガストリンワクチン、イトリグルミド(itriglumide)およびZ-360;
(v)5-HT3アンタゴニスト、例、ドラセトロン(dolasetron)、パロノセトロン(palonosetron)、アロセトロン(alosetron)、アザセトロン(azasetron)、ラモセトロン(ramosetron)、ミトラザピン(mitrazapine)、グラニセトロン(granisetron)、トロピセトロン(tropisetron)、E-3620、オンダンセトロン(ondansetron)およびインジセトロン(indisetron);
(vi)5-HT4アゴニスト、例、テガセロド(tegaserod)、モサプリド(mosapride)、シニタプリド(cinitapride)およびオキシトリプタン(oxtriptane);
(vii)緩下剤、例、Trifyba、Fybogel、Konsyl、Isogel、Regulan、CelevacおよびNormacol;
(viii)GABABアゴニスト、例、バクロフェン(baclofen)およびAZD-3355;
(ix)GABABアンタゴニスト、例、GAS-360およびSGS-742;
(x)カルシウムチャネルブロッカー、例、アラニジピン(aranidipine)、ラシジピン(lacidipine)、ファロジピン(falodipine)、アゼルニジピン(azelnidipine)、クリニジピン(clinidipine)、ロメリジン(lomerizine)、ジルチアゼム(diltiazem)、ガロパミル(gallopamil)、エフォニジピン(efonidipine)、ニソルピジン(nisoldipine)、アムロジピン(amlodipine)、レルカニジピン(lercanidipine)、ベバントロール(bevantolol)、ニカルジピン(nicardipine)、イスラジピン(isradipine)、ベニジピン(benidipine)、ベラパミル(verapamil)、ニトレンジピン(nitrendipine)、バルニジピン(barnidipine)、プロパフェノン(propafenone)、マニジピン(manidipine)、ベプリジル(bepridil)、ニフェジピン(nifedipine)、ニルバジピン(nilvadipine)、ニモジピン(nimodipine)およびファスジル(fasudil);
(xi)ドーパミンアンタゴニスト、例、メトクロプラミド(metoclopramide)、ドンペリドン(domperidone)およびレボスルピリド(levosulpiride);
(xii)タキキニン(NK)アンタゴニスト、特に、NK-3、NK-2およびNK-1アンタゴニスト、例、ネパズタント(nepadutant)、サレズタント(saredutant)、タルネタント(talnetant)、(αR,9R)-7-[3,5-ビス(トリフルオロメチル)ベンジル]-8,9,10,11-テトラヒドロ-9-メチル-5-(4-メチルフェニル)-7H-[1,4]ジアゾシノ[2,1-g][1,7]ナフチリジン-6-13-ジオン(TAK-637)、5-[(2R,3S)-2-[(1R)-1-[3,5-ビス(トリフルオロメチル)フェニル]エトキシ-3-(4-フルオロフェニル)-4-モルホリニル]メチル]-1,2-ジヒドロ-3H-1,2,4-トリアゾール-3-オン(MK-869)、ラネピタント(lanepitant)、ダピタント(dapitant)および3-[[2-メトキシ-5-(トリフルオロメトキシ)フェニル]メチルアミノ]-2-フェニル-ピペリジン(2S,3S);
(xiii)一酸化窒素シンターゼ阻害薬、例、GW-274150、ティラルギニン(tilarginine)、P54、グアニジオエチルジスルフィド(guanidioethyldisulfide)およびニトロフルビプロフェン(nitroflurbiprofen);
(xiv)バニロイドレセプター1アンタゴニスト、例、AMG-517およびGW-705498;
(xv)グレリンアゴニスト、例、カプロモレリン(capromorelin)およびTZP-101;
(xvi)AchE放出刺激剤、例、Z-338およびKW-5092。
s:シングレット(singlet)、d:ダブレット(doublet)、dd:ダブルダブレット(double doublet)、ddd:トリプルダブレット(triple doublet)、dt:ダブルトリプレット(double triplet)、t:トリプレット(triplet)、q:カルテット(quartet)、dq:ダブルカルテット(double quartet)、m:マルチプレット(multiplet)、br:ブロード(broad)、brs:ブロードシングレット(broad singlet)、J:カップリング定数(coupling constant)、Hz:ヘルツ(Hertz)。
1-(2-フルオロピリジン-3-イル)-5-ヒドロキシ-1H-ピラゾール-3-カルボン酸エチル
2-フルオロ-3-ヒドラジノピリジン(30.0g)のエタノール(472mL)溶液に炭酸ナトリウム(65.2g)およびブタ-2-イン二酸ジエチル(40.2g)を加えた。18時間還流した後、室温まで冷却し2mol/L塩酸で処理し、酢酸エチルで2回抽出した。抽出液を無水硫酸ナトリウムで乾燥し減圧濃縮した。残留物をジエチルエーテルに懸濁し、得られた固体をろ過後、減圧乾燥することで、表題化合物を黄色固体として得た(収量20.0g,収率34%)。
1H-NMR(DMSO-d6)δ:1.28(3H,t,J=7.2Hz),4.23(2H,q,J=7.2Hz),5.94(1H,s),7.57(1H,ddd,J=7.6,4.8,1.2Hz),7.49(1H,ddd,J=9.6,7.6,1.6Hz),8.39(1H,dt,J=4.8,1.6Hz),12.3(1H,brs).
1-(2-フルオロピリジン-3-イル)-5-{[(トリフルオロメチル)スルホニル]オキシ}-1H-ピラゾール-3-カルボン酸エチル
1-(2-フルオロピリジン-3-イル)-5-ヒドロキシ-1H-ピラゾール-3-カルボン酸エチル(2.0g)のテトラヒドロフラン(20mL)溶液に、トリエチルアミン(966mg)およびN-フェニルビス(トリフルオロメタンスルホンイミド)(3.1g)を加えた。室温で15分間撹拌した後、反応液に水を加え、酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=19:1→9:1)で精製することにより、表題化合物を黄色油状物として得た(収量2.1g、収率70%)。
1H-NMR(CDCl3)δ:1.43(3H,t,J=7.2Hz),4.46(2H,q,J=7.2Hz),6.88(1H,s),7.40-7.45(1H,m),7.99-8.06(1H,m),8.40-8.43(1H,m).
5-[(4-フルオロフェニル)スルファニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル
1-(2-フルオロピリジン-3-イル)-5-{[(トリフルオロメチル)スルホニル]オキシ}-1H-ピラゾール-3-カルボン酸エチル(353mg)、4-フルオロベンゼンチオール(130mg)および炭酸ナトリウム(146mg)のトルエン(5mL)溶液を充分脱気した後、トリス(ジベンジリデンアセトン)二パラジウム(0)(8.4mg)および4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(11mg)を加えて、さらに脱気した。アルゴン雰囲気下110℃で3時間撹拌した後、反応液を室温に戻し、酢酸エチルを加え、シリカゲルパッドでろ過した。ろ液の有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=19:1→2:1)で精製することにより、粗表題化合物を黄色油状物として得た(収量203mg)。
5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル
粗5-[(4-フルオロフェニル)スルファニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル(203mg)の酢酸エチル(3mL)溶液に3-クロロ過安息香酸(596mg)を加えた。室温で2時間撹拌した後、飽和チオ硫酸ナトリウム水溶液を加えて処理し、酢酸エチルで抽出した。抽出液を水、飽和炭酸水素ナトリウム水溶液、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物を塩基性シリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、表題化合物を無色油状物として得た(収量171mg、2工程収率47%)。
1H-NMR(CDCl3)δ:1.41(3H,t,J=7.2Hz),4.44(2H,q,J=7.2Hz),7.10-7.20(2H,m),7.40(1H,ddd,J=7.8,4.9,0.9Hz),7.54-7.65(3H,m),7.93(1H,ddd,J=9.2,7.5,1.9Hz),8.41(1H,dt,J=4.9,1.5Hz).
{5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メタノール
5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル(170mg)のテトラヒドロフラン(2.5mL)溶液を-78℃に冷却し、1.5mol/L水素化ジイソブチルアルミニウムのトルエン溶液(1.2mL)を滴下した。反応液を室温で1時間撹拌した後、1mol/L塩酸を加えて処理し、酢酸エチルで抽出した。抽出液を水、飽和炭酸水素ナトリウム水溶液、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、表題化合物を黄色固体として得た(収量135mg、収率89%)。
1H-NMR(CDCl3)δ:4.77(2H,s),7.05-7.19(3H,m),7.32-7.43(1H,m),7.52-7.63(2H,m),7.91(1H,ddd,J=9.1,7.6,1.9Hz),8.35-8.41(1H,m),1H未検出.
5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルバルデヒド
{5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メタノール(135mg)をトルエン(2mL)に溶解し、二酸化マンガン(167mg)を加えて、100℃で42時間撹拌した。反応液を室温に戻し、セライトろ過した。ろ液を減圧濃縮し、残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=19:1→3:1)で精製することにより、表題化合物を無色油状物として得た(収量108mg、収率80%)。
1H-NMR(CDCl3)δ:7.11-7.21(2H,m),7.45(1H,ddd,J=7.8,4.9,0.9Hz),7.53(1H,s),7.55-7.64(2H,m),7.98(1H,ddd,J=9.1,7.6,1.9Hz),8.45(1H,dt,J=4.9,1.5Hz),10.00(1H,s).
({5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル
5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルバルデヒド(108mg)のメタノール(2mL)溶液に、塩化メチルアンモニウム(23mg)、無水硫酸マグネシウム(56mg)およびトリエチルアミン(34mg)を加えた。3時間室温で撹拌した後、氷冷下水素化ホウ素ナトリウム(14mg)を加えた。溶媒を減圧留去し、残留物に水と酢酸エチルを加え、二炭酸ジ-tert-ブチル(101mg)を加えた。反応液を有機層と水層に分離し、分離した水層を再度酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、表題化合物を無色油状物として得た(収量132mg、収率93%)。
1H-NMR(CDCl3)δ:1.49(9H,s),2.89(3H,brs),4.45(2H,brs),7.03(1H,brs),7.08-7.18(2H,m),7.37(1H,dd,J=7.4,5.2Hz),7.50-7.63(2H,m),7.85-7.97(1H,m),8.31-8.40(1H,m).
1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルファニル]-1H-ピラゾール-3-カルボン酸エチル
1-(2-フルオロピリジン-3-イル)-5-{[(トリフルオロメチル)スルホニル]オキシ}-1H-ピラゾール-3-カルボン酸エチル(351mg)、4-メトキシベンゼンチオール(141mg)および炭酸ナトリウム(146mg)のトルエン(5mL)溶液を充分脱気した後、トリス(ジベンジリデンアセトン)二パラジウム(0)(17mg)および4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(21mg)を加えて、さらに脱気した。アルゴン雰囲気下110℃で13時間撹拌した後、反応液を室温に戻し、酢酸エチルを加え、シリカゲルパッドでろ過した。ろ液の有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、粗表題化合物を黄色油状物として得た。
1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-カルボン酸エチル
参考例4の方法に従い、粗5-[(4-フルオロフェニル)スルファニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチルの代わりに粗1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルファニル]-1H-ピラゾール-3-カルボン酸エチルを用いて合成した(2工程収率46%)。
1H-NMR(CDCl3)δ:1.41(3H,t,J=6.9Hz),3.87(3H,s),4.44(2H,q,J=7.3Hz),6.85-6.95(2H,m),7.38(1H,dd,J=7.6,4.8Hz),7.44-7.51(2H,m),7.53(1H,s),7.86-8.00(1H,m),8.39(1H,d,J=5.0Hz).
{1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-イル}メタノール
参考例5の方法に従い、5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチルの代わりに1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-カルボン酸エチルを用いて合成した(収率97%)。
1H-NMR(CDCl3)δ:1.97-2.05(1H,m),3.86(3H,s),4.76(2H,d,J=5.8Hz),6.84-6.92(2H,m),7.08(1H,s),7.36(1H,ddd,J=7.7,5.0,1.1Hz),7.43-7.50(2H,m),7.91(1H,ddd,J=9.2,7.6,1.9Hz),8.35(1H,dt,J=4.8,1.4Hz).
1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-カルバルデヒド
参考例6の方法に従い、{5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メタノールの代わりに{1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-イル}メタノールを用いて合成した(収率91%)。
1H-NMR(CDCl3)δ:3.87(3H,s),6.86-6.95(2H,m),7.39-7.53(4H,m),7.94-8.05(1H,m),8.43(1H,d,J=5.0Hz),9.99(1H,s).
1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルファニル]-1H-ピラゾール-3-カルボン酸エチル
1-(2-フルオロピリジン-3-イル)-5-{[(トリフルオロメチル)スルホニル]オキシ}-1H-ピラゾール-3-カルボン酸エチル(575mg)、3-メチルベンゼンチオール(224mg)および炭酸ナトリウム(238mg)のトルエン(7.5mL)溶液を充分脱気した後、トリス(ジベンジリデンアセトン)二パラジウム(0)(41mg)および4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(52mg)を加えて、さらに脱気した。アルゴン雰囲気下130℃で28時間撹拌した後、反応液を室温に戻し、酢酸エチルを加え、塩基性シリカゲルパッドでろ過した。ろ液を減圧濃縮し、得られた残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、粗表題化合物を黄色油状物として得た(収量334mg)。
1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-カルボン酸エチル
粗1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルファニル]-1H-ピラゾール-3-カルボン酸エチル(334mg)の酢酸エチル(7.5mL)溶液に3-クロロ過安息香酸(1.59g)を加えた。室温で3時間撹拌した後、飽和チオ硫酸ナトリウム水溶液を加えて処理し、酢酸エチルで抽出した。抽出液を水、飽和炭酸水素ナトリウム水溶液、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、表題化合物を無色油状物として得た(収量384mg、2工程収率62%)。
1H-NMR(CDCl3)δ:1.41(3H,t,J=7.2Hz),2.35(3H,s),4.44(2H,q,J=6.9Hz),7.29(1H,s),7.32-7.41(3H,m),7.41-7.48(1H,m),7.60(1H,s),7.92(1H,ddd,J=9.1,7.6,1.9Hz),8.39(1H,dt,J=4.6,1.5Hz).
{1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}メタノール
1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-カルボン酸エチル(384mg)のテトラヒドロフラン(5mL)溶液を-78℃に冷却し、1.5mol/L水素化ジイソブチルアルミニウムのトルエン溶液(2.6mL)を滴下した。反応液を0℃で1時間撹拌した後、1mol/L塩酸を加えて処理し、酢酸エチルで抽出した。抽出液を水、飽和炭酸水素ナトリウム水溶液、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、表題化合物を無色油状物として得た(収量320mg、収率94%)
1H-NMR(CDCl3)δ:2.00(1H,brs),2.34(3H,s),4.77(2H,d,J=4.2Hz),7.15(1H,s),7.28(1H,s),7.30-7.45(4H,m),7.91(1H,ddd,J=9.2,7.5,1.9Hz),8.35(1H,dt,J=4.9,1.5Hz).
1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-カルバルデヒド
{1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}メタノール(320mg)をトルエン(5mL)に溶解し、二酸化マンガン(802mg)を加えて、90℃で4時間撹拌した。反応液を室温に戻し、セライトろ過した。ろ液を減圧濃縮し、残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、表題化合物を無色油状物として得た(収量266mg、収率83%)。
1H-NMR(CDCl3)δ:2.35(3H,s),7.30(1H,s),7.32-7.39(2H,m),7.39-7.49(2H,m),7.53(1H,s),7.98(1H,ddd,J=9.1,7.6,1.9Hz),8.43(1H,dt,J=4.9,1.5Hz),10.00(1H,s).
({1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル
1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-カルバルデヒド(265mg)のメタノール(4mL)溶液に、塩化メチルアンモニウム(57mg)、無水硫酸マグネシウム(139mg)およびトリエチルアミン(85mg)を加えた。2時間室温で撹拌した後、氷冷下水素化ホウ素ナトリウム(35mg)を加え、更に室温で1時間撹拌した。溶媒を減圧留去し、残留物に水と酢酸エチルを加え、二炭酸ジ-tert-ブチル(251mg)を加えた。反応液を有機層と水層に分離し、分離した水層を再度酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物を塩基性シリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、表題化合物を無色油状物として得た(収量302mg、収率85%)。
1H-NMR(CDCl3)δ:1.49(9H,s),2.34(3H,s),2.90(3H,brs),4.45(2H,brs),7.03(1H,brs),7.22-7.48(5H,m),7.85-7.97(1H,m),8.34(1H,dt,J=3.3,1.6Hz).
5-[(3-ブロモフェニル)スルファニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル
1-(2-フルオロピリジン-3-イル)-5-{[(トリフルオロメチル)スルホニル]オキシ}-1H-ピラゾール-3-カルボン酸エチル(767mg)、3-ブロモベンゼンチオール(567mg)および炭酸ナトリウム(424mg)のトルエン(10mL)溶液を充分脱気した後、トリス(ジベンジリデンアセトン)二パラジウム(0)(92mg)および4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(116mg)を加えて、さらに脱気した。アルゴン雰囲気下110℃で16時間撹拌した後、反応液を室温に戻し、酢酸エチルを加え、塩基性シリカゲルパッドでろ過した。ろ液を減圧濃縮し、残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、粗表題化合物を黄色油状物として得た(収量869mg)。
5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル
粗5-[(3-ブロモフェニル)スルファニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル(869mg)の酢酸エチル(10mL)溶液に3-クロロ過安息香酸(2.73g)を加えた。室温で3時間撹拌した後、飽和チオ硫酸ナトリウム水溶液を加えて処理し、酢酸エチルで抽出した。抽出液を水、飽和炭酸水素ナトリウム水溶液、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物を塩基性シリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=19:1→4:1)で精製することにより、表題化合物を無色油状物として得た(収量410mg、2工程収率45%)。
1H-NMR(CDCl3)δ:1.41(3H,t,J=7.2Hz),4.45(2H,q,J=6.9Hz),7.31-7.46(2H,m),7.49-7.55(1H,m),7.60(1H,t,J=1.7Hz),7.63(1H,s),7.77(1H,dq,J=8.0,1.0Hz),7.90(1H,ddd,J=9.1,7.6,1.9Hz),8.43(1H,dt,J=4.7,1.6Hz).
{5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メタノール
5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルボン酸エチル(467mg)のテトラヒドロフラン(5mL)溶液を-78℃に冷却し、1.5mol/L水素化ジイソブチルアルミニウムのトルエン溶液(2.7mL)を滴下した。反応液を0℃で2時間撹拌した後、1mol/L塩酸を加えて処理し、酢酸エチルで抽出した。抽出液を水、飽和炭酸水素ナトリウム水溶液、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、表題化合物を黄色油状物として得た(収量371mg、収率88%)。
1H-NMR(CDCl3)δ:2.19(1H,brs),4.77(2H,brs),7.19(1H,s),7.29-7.43(2H,m),7.50(1H,dq,J=8.0,1.0Hz),7.60(1H,t,J=1.9Hz),7.69-7.79(1H,m),7.88(1H,ddd,J=9.1,7.6,1.9Hz),8.39(1H,dt,J=4.7,1.6Hz).
5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルバルデヒド
{5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メタノール(371mg)をトルエン(5mL)に溶解し、二酸化マンガン(626mg)を加えて、90℃で5時間撹拌した。反応液を室温に戻し、セライトろ過した。ろ液を減圧濃縮し、残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=19:1→3:1)で精製することにより、表題化合物を無色固体として得た(収量280mg、収率76%)。
1H-NMR(CDCl3)δ:7.32-7.42(1H,m),7.42-7.49(1H,m),7.53(1H,dt,J=7.9,1.3Hz),7.57-7.63(2H,m),7.78(1H,dq,J=7.9,1.0Hz),7.96(1H,ddd,J=9.1,7.6,2.1Hz),8.47(1H,dt,J=4.9,1.5Hz),10.01(1H,s).
({5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル
5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-カルバルデヒド(270mg)のメタノール(3.5mL)溶液に、塩化メチルアンモニウム(49mg)、無水硫酸マグネシウム(119mg)およびトリエチルアミン(73mg)を加えた。3時間室温で撹拌した後、氷冷下水素化ホウ素ナトリウム(37mg)を加え、更に室温で1時間撹拌した。溶媒を減圧留去し、残留物に水と酢酸エチルを加え、二炭酸ジ-tert-ブチル(215mg)を加えた。反応液を有機層と水層に分離し、分離した水層を再度酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、表題化合物を無色油状物として得た(収量315mg、収率91%)。
1H-NMR(CDCl3)δ:1.49(9H,s),2.90(3H,brs),4.46(2H,brs),7.08(1H,brs),7.30-7.43(2H,m),7.50(1H,d,J=8.0Hz),7.58(1H,t,J=1.9Hz),7.74(1H,dq,J=8.2,0.8Hz),7.89(1H,ddd,J=9.2,7.5,1.9Hz),8.38(1H,dt,J=4.9,1.5Hz).
({5-[(3-シアノフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル
({5-[(3-ブロモフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル(315mg)およびシアン化亜鉛(107mg)のジメチルホルムアミド(3mL)溶液を充分脱気した後、テトラキス(トリフェニルホスフィン)パラジウム(0)(138mg)を加えて、さらに脱気した。アルゴン雰囲気下110℃で2時間撹拌した後、反応液を室温に戻し、反応液を水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン-酢酸エチル=9:1→2:1)で精製することにより、表題化合物を黄色油状物として得た(収量247mg、収率87%)。
1H-NMR(CDCl3)δ:1.50(9H,s),2.91(3H,brs),4.47(2H,brs),7.13(1H,brs),7.42(1H,dd,J=7.9,4.9Hz),7.57-7.67(1H,m),7.70-7.83(2H,m),7.85-8.00(2H,m),8.41(1H,dt,J=4.9,1.3Hz).
1-{5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}-N-メチルメタンアミン 塩酸塩
({5-[(4-フルオロフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル(132mg)を酢酸エチル(2mL)および2-プロパノール(1mL)に溶解し、4mol/L塩化水素-酢酸エチル溶液(3mL)を加えた。室温で2時間撹拌した後、反応混合物を減圧濃縮後、残留物をエタノールと酢酸エチルの混合溶媒から再結晶することにより表題化合物を無色結晶として得た(収量83mg、収率73%)。融点211-214℃。
1H-NMR(DMSO-d6)δ:2.59(3H,s),4.25(2H,s),7.41-7.51(2H,m),7.52(1H,s),7.56-7.70(3H,m),8.11(1H,ddd,J=9.5,7.8,1.9Hz),8.51(1H,dt,J=4.9,1.5Hz),9.24(2H,brs).
1-{1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミン 塩酸塩
参考例7と同様の方法を用いて1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-カルバルデヒドを還元的アミノ化した後に、4mol/L塩化水素―酢酸エチル溶液を用いて合成した。融点222-225℃。
1H-NMR(DMSO-d6)δ:2.58(3H,s),3.85(3H,s),4.23(2H,s),7.06-7.15(2H,m),7.41-7.52(3H,m),7.60(1H,dd,J=7.7,5.0Hz),8.07(1H,ddd,J=9.6,7.7,1.9Hz),8.44-8.58(1H,m),9.27(2H,brs).
1-{1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミン 塩酸塩
({1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル(302mg)を酢酸エチル(2mL)および2-プロパノール(1mL)に溶解し、4mol/L塩化水素-酢酸エチル溶液(3mL)を加えた。室温で2時間撹拌した後、反応混合物を減圧濃縮後、残留物をエタノールから再結晶することにより表題化合物を無色結晶として得た(収量216mg、収率83%)。融点202-205℃。
1H-NMR(DMSO-d6)δ:2.32(3H,s),2.59(3H,s),4.25(2H,s),7.25(1H,s),7.34-7.41(1H,m),7.46-7.53(2H,m),7.54-7.67(2H,m),8.09(1H,ddd,J=9.5,7.8,1.9Hz),8.51(1H,dt,J=4.9,1.5Hz),9.24(2H,brs).
3-({1-(2-フルオロピリジン-3-イル)-3-[(メチルアミノ)メチル]-1H-ピラゾール-5-イル}スルホニル)ベンゾニトリル 塩酸塩
({5-[(3-シアノフェニル)スルホニル]-1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}メチル)メチルカルバミン酸 tert-ブチル(247mg)を酢酸エチル(2mL)および2-プロパノール(1mL)に溶解し、4mol/L塩化水素-酢酸エチル溶液(3mL)を加えた。室温で3時間撹拌した後、反応混合物を減圧濃縮後、残留物をエタノールと水の混合溶媒から再結晶することにより表題化合物を無色結晶として得た(収量184mg、収率86%)。融点237-240℃。
1H-NMR(DMSO-d6)δ:2.60(3H,s),4.26(2H,s),7.58-7.67(2H,m),7.79-7.88(1H,m),7.88-7.96(1H,m),8.04(1H,t,J=1.7Hz),8.14(1H,ddd,J=9.6,7.7,2.1Hz),8.28(1H,dt,J=7.6,1.3Hz),8.47-8.58(1H,m),9.25(2H,brs).
プロトン・カリウム-アデノシントリホスファターゼ(H+,K+-ATPase)阻害活性試験
ウォールマーク(Wallmark)らの方法[Biochim.Biophys.Acta,728,31(1983年)]に準じて胃粘膜ミクロソーム画分をブタの胃から調製した。まず、胃体部を摘出後、水道水で洗浄した後、3mol/L食塩水に浸し、ペーパータオルで粘膜表面を拭いた。胃粘膜を剥離し、細切後、1mmol/L EDTAおよび10mmol/Lトリス塩酸を含む0.25mol/L蔗糖液(pH6.8)中でポリトロン(キネマティカ)を用いてホモジナイズした。得られたホモジネートを20,000×gで30分間遠心分離後、上清を100,000×gで90分間遠心分離した。沈殿部を0.25mol/L蔗糖液で懸濁後、7.5%フィコールを含む0.25mol/L蔗糖液上に重層し、100,000×gで5時間遠心分離した。両層の界面部画分を回収し、0.25mol/L蔗糖液で遠心洗浄を行った。
Advanced Chemistry Developmet,Inc.のPhyschem Batch(Ver.10)を用いてpKa値を計算により求めた。その結果を表1に示す。
ATP含量試験
ヒト肝ガン由来細胞株HepG2(ATCC No.HB-8065)は、10%ウシ胎児血清(fetal bovine serum;FBS;TRACE SCIENTIFIC LTD.)、1mmol/Lピルビン酸ナトリウム(Invitrogen)、2mmol/L L-グルタミン(Invitrogen)、50IU/mLペニシリン(Invitrogen)、50μg/mLストレプトマイシン(Invitrogen)を含むDulbecco's modified Eagle medium(DMEM;Invitrogen)培地を用いて5%CO2、37℃で維持・継代した。被検試薬は、DMSOにて10mMに調製し、さらに、0.5%FBS、1mmol/Lピルビン酸ナトリウム、2mmol/L L-グルタミン、50IU/mLペニシリン、50μg/mLストレプトマイシンを含むDMEM培地を用いてDMSOの最終濃度が0.1%となるように希釈した。96ウェル白色プレート(Costar)上でHepG2(2x104cells/well)を被検試薬と共に5%CO2、37℃で培養した。1日培養後、細胞内のATP含量をATPLiteTM(PerkinElmer Life Sciences)を用いて測定した。その結果を100μMでのコントロール(薬物無添加)に対する相対値(%)として表1に示す(n≧3,平均値±SD)。
Caspase-3/7活性試験
試験例3と同様の方法で1日培養した細胞内のCaspase-3/7活性をCaspase-Glo 3/7Assay(Promega)を用いて測定した。その結果をスタウロスポリンを曝露させた時のCaspase-3/7活性の最大値を100%、被検試薬無添加時の活性を0%とした各被検試薬の相対的な活性(%)として表1に示す(n≧3,平均値±SD)。
試験例5
麻酔ラットを用いたヒスタミン刺激酸分泌の抑制試験
7週齢のJcl:SD雄性ラットを約24時間絶食後、実験に用いた。ウレタン(1.2 g/kg、i.p.)麻酔下に腹部を正中線に沿って切開し幽門輪を結さつした。被験薬物(1mg/kg)を静脈内投与し、腹部切開口を縫合した後、生理食塩液に溶解したヒスタミン2塩酸塩30 mg/kg/10 mLを皮下投与した。ヒスタミン投与の3時間後、ラットを炭酸ガスで致死させ胃を摘出して貯留胃液を採取した。胃液量及び酸滴定装置COM-555(平沼産業)を用いて酸度を測定し、その積を酸分泌量とした。対照との比較から被験薬物の酸分泌抑制率を求めた。その結果を表1に示す。
本出願は、日本で出願された特願2009-077078を基礎としており、その内容は本明細書にすべて包含される。
Claims (16)
- R1が、水素原子以外の原子数1~7個で形成される置換基である請求項1記載の化合物またはその塩。
- R1が、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基または置換されていてもよいC1-6アルコキシ基である請求項1記載の化合物またはその塩。
- R2が、水素原子、C1-6アルキル基またはシアノ基である請求項1記載の化合物またはその塩。
- R3が、水素原子、ハロゲン原子、C1-6アルキル基またはC1-6アルコキシ基である請求項1記載の化合物またはその塩。
- 1-{5-[(4-フルオロフェニル)スルホニル] -1-(2-フルオロピリジン-3-イル)-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩。
- 1-{1-(2-フルオロピリジン-3-イル)-5-[(4-メトキシフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩。
- 1-{1-(2-フルオロピリジン-3-イル)-5-[(3-メチルフェニル)スルホニル]-1H-ピラゾール-3-イル}-N-メチルメタンアミンまたはその塩。
- 3-({1-(2-フルオロピリジン-3-イル)-3-[(メチルアミノ)メチル]-1H-ピラゾール-5-イル}スルホニル)ベンゾニトリルまたはその塩。
- 請求項1記載の化合物またはその塩のプロドラッグ。
- 請求項1記載の化合物もしくはその塩またはそのプロドラッグを含有してなる医薬。
- 酸分泌抑制剤である請求項11記載の医薬。
- カリウムイオン競合型アシッドブロッカー(Potassium-Competitive Acid Blocker)である請求項11記載の医薬。
- 消化性潰瘍、ゾリンジャー・エリソン(Zollinger-Ellison)症候群、胃炎、逆流性食道炎、症候性胃食道逆流症(Symptomatic Gastroesophageal Reflux Disease(Symptomatic GERD))、Barrett食道、機能性ディスペプシア(Functional Dyspepsia)、胃癌、胃MALTリンパ腫、非ステロイド系抗炎症剤に起因する潰瘍あるいは手術後ストレスによる胃酸過多ならびに潰瘍の治療もしくは予防剤;または消化性潰瘍、急性ストレス潰瘍、出血性胃炎あるいは侵襲ストレスによる上部消化管出血の抑制剤である請求項11記載の医薬。
- 哺乳動物に対して、請求項1記載の化合物もしくはその塩またはそのプロドラッグの有効量を投与することを特徴とする消化性潰瘍、ゾリンジャー・エリソン(Zollinger-Ellison)症候群、胃炎、逆流性食道炎、症候性胃食道逆流症(Symptomatic Gastroesophageal Reflux Disease(Symptomatic GERD))、Barrett食道、機能性ディスペプシア(Functional Dyspepsia)、胃癌、胃MALTリンパ腫、非ステロイド系抗炎症剤に起因する潰瘍あるいは手術後ストレスによる胃酸過多ならびに潰瘍の治療または予防方法;または消化性潰瘍、急性ストレス潰瘍、出血性胃炎あるいは侵襲ストレスによる上部消化管出血の抑制方法。
- 消化性潰瘍、ゾリンジャー・エリソン(Zollinger-Ellison)症候群、胃炎、逆流性食道炎、症候性胃食道逆流症(Symptomatic Gastroesophageal Reflux Disease(Symptomatic GERD))、Barrett食道、機能性ディスペプシア(Functional Dyspepsia)、胃癌、胃MALTリンパ腫、非ステロイド系抗炎症剤に起因する潰瘍あるいは手術後ストレスによる胃酸過多ならびに潰瘍の治療もしくは予防剤;または消化性潰瘍、急性ストレス潰瘍、出血性胃炎あるいは侵襲ストレスによる上部消化管出血の抑制剤を製造するための請求項1記載の化合物もしくはその塩またはそのプロドラッグの使用。
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10756174.8A EP2412713B1 (en) | 2009-03-26 | 2010-03-25 | Pyrazole compound |
MX2011009943A MX2011009943A (es) | 2009-03-26 | 2010-03-25 | Compuesto de pirazol. |
US13/260,507 US8895588B2 (en) | 2009-03-26 | 2010-03-25 | Pyrazole compound |
EA201171168A EA019853B1 (ru) | 2009-03-26 | 2010-03-25 | Производные 1-(пиридин-3-ил)-3-метиламинометил-5-фенилсульфонилпиразола |
JP2011506117A JP5552481B2 (ja) | 2009-03-26 | 2010-03-25 | ピラゾール化合物 |
UAA201112488A UA107457C2 (uk) | 2009-03-26 | 2010-03-25 | Похідні піразолу |
MA34275A MA33214B1 (fr) | 2009-03-26 | 2010-03-25 | Compose pyrazole |
CN201080023162.7A CN102448953B (zh) | 2009-03-26 | 2010-03-25 | 吡唑化合物 |
CA2756086A CA2756086A1 (en) | 2009-03-26 | 2010-03-25 | Pyrazole compound |
NZ595890A NZ595890A (en) | 2009-03-26 | 2010-03-25 | Pyrazole compound |
SG2011067808A SG174476A1 (en) | 2009-03-26 | 2010-03-25 | Pyrazole compound |
AU2010228220A AU2010228220B2 (en) | 2009-03-26 | 2010-03-25 | Pyrazole compound |
BRPI1009090A BRPI1009090A2 (pt) | 2009-03-26 | 2010-03-25 | composto, pró-droga, medicamento, métodos, e, uso do composto |
IL215235A IL215235A (en) | 2009-03-26 | 2011-09-19 | An antimicrobial compound, a drug containing the compound, the use of a compound for the preparation of a preparation for the prevention or treatment of a digestive ulcer |
TN2011000474A TN2011000474A1 (en) | 2009-03-26 | 2011-09-21 | Pyrazole compound |
ZA2011/07435A ZA201107435B (en) | 2009-03-26 | 2011-10-11 | Pyrazole copmpound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-077078 | 2009-03-26 | ||
JP2009077078 | 2009-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010110378A1 true WO2010110378A1 (ja) | 2010-09-30 |
Family
ID=42781069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/055257 WO2010110378A1 (ja) | 2009-03-26 | 2010-03-25 | ピラゾール化合物 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8895588B2 (ja) |
EP (1) | EP2412713B1 (ja) |
JP (1) | JP5552481B2 (ja) |
KR (1) | KR101656906B1 (ja) |
CN (1) | CN102448953B (ja) |
AU (1) | AU2010228220B2 (ja) |
BR (1) | BRPI1009090A2 (ja) |
CA (1) | CA2756086A1 (ja) |
CL (1) | CL2011002351A1 (ja) |
CO (1) | CO6460700A2 (ja) |
CR (1) | CR20110533A (ja) |
DO (1) | DOP2011000296A (ja) |
EA (1) | EA019853B1 (ja) |
EC (1) | ECSP11011419A (ja) |
GE (1) | GEP20156222B (ja) |
IL (1) | IL215235A (ja) |
MA (1) | MA33214B1 (ja) |
MX (1) | MX2011009943A (ja) |
NZ (1) | NZ595890A (ja) |
PE (1) | PE20120618A1 (ja) |
SG (1) | SG174476A1 (ja) |
TN (1) | TN2011000474A1 (ja) |
UA (1) | UA107457C2 (ja) |
WO (1) | WO2010110378A1 (ja) |
ZA (1) | ZA201107435B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014003199A1 (en) | 2012-06-27 | 2014-01-03 | Takeda Pharmaceutical Company Limited | Liquid preparations of amines and organic acids stabilized by salts |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220003640A (ko) * | 2012-09-27 | 2022-01-10 | 아라타나 세라퓨틱스, 인크. | 식욕부진을 조절 화합물 조성물 및 이의 이용 방법 |
CA2974012C (en) | 2015-01-28 | 2020-08-18 | Aratana Therapeutics, Inc. | Compositions and methods for chronic use of a weight-gaining compound |
CN105067814A (zh) * | 2015-07-24 | 2015-11-18 | 中国科学院成都生物研究所 | 解旋酶水解atp活性测定方法 |
KR102432523B1 (ko) * | 2020-06-17 | 2022-08-16 | 일동제약(주) | 신규한 산 분비 억제제 및 이의 용도 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098589A1 (en) | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
WO2007026916A1 (en) * | 2005-08-30 | 2007-03-08 | Takeda Pharmaceutical Company Limited | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
WO2007114338A1 (ja) * | 2006-03-31 | 2007-10-11 | Takeda Pharmaceutical Company Limited | 酸分泌抑制薬 |
WO2008108380A2 (en) * | 2007-02-28 | 2008-09-12 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
WO2009041705A2 (en) * | 2007-09-28 | 2009-04-02 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compounds as proton pump inhibitors |
JP2009077078A (ja) | 2007-09-19 | 2009-04-09 | Brother Ind Ltd | 位置検出システム |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3285991A (en) | 1963-03-26 | 1966-11-15 | Union Carbide Corp | Polyepoxides cured with the reaction product of a dihydroxydiphenylsul-fone, an amine, and an aldehyde |
US4847289A (en) | 1987-06-08 | 1989-07-11 | Merck & Co., Inc. | Thiophene sulfonamide antiglaucoma agents |
ZA927272B (en) | 1991-10-29 | 1994-03-23 | Du Pont | Herbicidal triazolecarboxamides |
ES2211917T3 (es) | 1994-09-26 | 2004-07-16 | SHIONOGI & CO., LTD. | Derivado de imidazol. |
JPH0948778A (ja) | 1995-08-04 | 1997-02-18 | Sagami Chem Res Center | 2−置換−3−アルコキシ−5−(ピロール−2−イル)フラン誘導体 |
PT873123E (pt) | 1995-11-06 | 2003-08-29 | Univ Pittsburgh | Inibidores de proteina-isoprenil-transferase |
EP0946508B1 (en) | 1996-12-23 | 2009-09-23 | Bristol-Myers Squibb Pharma Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
WO1999042461A1 (en) | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
EP1534278A4 (en) | 2002-08-01 | 2006-09-06 | Nitromed Inc | NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD |
ATE482933T1 (de) | 2003-05-26 | 2010-10-15 | Takeda Pharmaceutical | Sulfopyrrolderivate |
EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
EP2336107B1 (en) | 2004-09-30 | 2015-09-23 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
JP5379690B2 (ja) | 2007-09-28 | 2013-12-25 | 武田薬品工業株式会社 | 5員複素環化合物 |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
WO2010007382A1 (en) | 2008-07-18 | 2010-01-21 | Takeda Pharmaceutical Company Limited. | Benzazepine derivatives and their use as hstamine h3 antagonists |
-
2010
- 2010-03-25 EP EP10756174.8A patent/EP2412713B1/en active Active
- 2010-03-25 WO PCT/JP2010/055257 patent/WO2010110378A1/ja active Application Filing
- 2010-03-25 AU AU2010228220A patent/AU2010228220B2/en not_active Ceased
- 2010-03-25 PE PE2011001696A patent/PE20120618A1/es not_active Application Discontinuation
- 2010-03-25 GE GEAP201012426A patent/GEP20156222B/en unknown
- 2010-03-25 JP JP2011506117A patent/JP5552481B2/ja active Active
- 2010-03-25 US US13/260,507 patent/US8895588B2/en active Active
- 2010-03-25 BR BRPI1009090A patent/BRPI1009090A2/pt not_active IP Right Cessation
- 2010-03-25 SG SG2011067808A patent/SG174476A1/en unknown
- 2010-03-25 KR KR1020117024240A patent/KR101656906B1/ko active IP Right Grant
- 2010-03-25 CA CA2756086A patent/CA2756086A1/en not_active Abandoned
- 2010-03-25 CN CN201080023162.7A patent/CN102448953B/zh active Active
- 2010-03-25 MA MA34275A patent/MA33214B1/fr unknown
- 2010-03-25 NZ NZ595890A patent/NZ595890A/xx not_active IP Right Cessation
- 2010-03-25 EA EA201171168A patent/EA019853B1/ru not_active IP Right Cessation
- 2010-03-25 MX MX2011009943A patent/MX2011009943A/es active IP Right Grant
- 2010-03-25 UA UAA201112488A patent/UA107457C2/uk unknown
-
2011
- 2011-08-25 EC EC2011011419A patent/ECSP11011419A/es unknown
- 2011-09-19 IL IL215235A patent/IL215235A/en not_active IP Right Cessation
- 2011-09-21 TN TN2011000474A patent/TN2011000474A1/fr unknown
- 2011-09-23 CL CL2011002351A patent/CL2011002351A1/es unknown
- 2011-09-23 DO DO2011000296A patent/DOP2011000296A/es unknown
- 2011-10-11 ZA ZA2011/07435A patent/ZA201107435B/en unknown
- 2011-10-12 CR CR20110533A patent/CR20110533A/es unknown
- 2011-10-26 CO CO11144548A patent/CO6460700A2/es active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098589A1 (en) | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
WO2007026916A1 (en) * | 2005-08-30 | 2007-03-08 | Takeda Pharmaceutical Company Limited | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
WO2007114338A1 (ja) * | 2006-03-31 | 2007-10-11 | Takeda Pharmaceutical Company Limited | 酸分泌抑制薬 |
WO2008108380A2 (en) * | 2007-02-28 | 2008-09-12 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
JP2009077078A (ja) | 2007-09-19 | 2009-04-09 | Brother Ind Ltd | 位置検出システム |
WO2009041705A2 (en) * | 2007-09-28 | 2009-04-02 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compounds as proton pump inhibitors |
Non-Patent Citations (12)
Title |
---|
"Jikken Kagaku Kouza", vol. 21, 1991, MARUZEN PRESS, pages: 106 - 124 |
"Pharmaceutical Research and Development", vol. 7, 1990, HIROKAWA PUBLISHING CO., article "Molecule Design", pages: 163 - 198 |
"Shinjikken Kagaku Kouza", vol. 14-III, MARUZEN PRESS, pages: 1380 - 1385 |
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 731 |
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 31, 1983, pages 1228 |
HETEROCYCLES, vol. 46, 1997, pages 489 |
JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 72, 1950, pages 745 |
See also references of EP2412713A4 |
SYNTHESIS, 1994, pages 639 |
TETRAHEDRON LETTERS, vol. 39, 1998, pages 2941 |
THEODORA W. GREENE, PETER G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE |
WALLMARK ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 728, 1983, pages 31 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014003199A1 (en) | 2012-06-27 | 2014-01-03 | Takeda Pharmaceutical Company Limited | Liquid preparations of amines and organic acids stabilized by salts |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5207964B2 (ja) | 酸分泌抑制薬 | |
JP5638515B2 (ja) | ピロール化合物 | |
JP5432718B2 (ja) | ピロール化合物 | |
EP2196459B1 (en) | 5-membered heterocyclic compound | |
JP5552481B2 (ja) | ピラゾール化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080023162.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10756174 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011506117 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2756086 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001696-2011 Country of ref document: PE Ref document number: MX/A/2011/009943 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011501914 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 0141411 Country of ref document: KE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010756174 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010756174 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000533 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 20117024240 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4282/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 595890 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: a201112488 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201171168 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11144548 Country of ref document: CO Ref document number: 13110724 Country of ref document: CO Ref document number: 12426 Country of ref document: GE |
|
ENP | Entry into the national phase |
Ref document number: 2010228220 Country of ref document: AU Date of ref document: 20100325 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13260507 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1009090 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1009090 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110922 |